| abstract |
In patients with a need for treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infection, compared to direct administration of indoximod, Indoximod prodrugs and salt compounds that increase plasma concentration and exposure to indoximod and pharmaceutical compositions comprising indoximod salts and prodrugs are provided. [Selection] Figure 6 |